Methylene Chloride

Methylene Chloride

SCHEMBL253265

ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.OCC(Cl)(Cl)CO

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL1159353 1.00 ALDH1A1 (0.33) ALDH1A1
Methylene Chloride SCHEMBL7421886 1.00 ALDH1A1 (0.33) ALDH1A1
Methylene Chloride SCHEMBL7249214 1.00 ALDH1A1 (0.33) ALDH1A1
Methylene Chloride SCHEMBL4264211 1.00 ALDH1A1 (0.33) ALDH1A1
Methylene Chloride SCHEMBL565915 1.00 ALDH1A1 (0.33) ALDH1A1
SCHEMBL1982189 0.91
Methane SCHEMBL10705120 0.87 MEN1 (0.31)
SCHEMBL9065354 0.80
SCHEMBL7598389 0.74 TP53 (0.33)
Methylene Chloride SCHEMBL28765651 0.70 ALDH1A1 (0.44) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 682 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115210287-B Epoxy amine adduct, curing catalyst, resin composition, sealing material, adhesive, and cured product 纳美仕有限公司 2024-07-02 CN disclosed
US-20240197923-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2024-06-20 US disclosed
WO-2024126617-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY CROSSFIRE ONCOLOGY HOLDING B.V. (NL) 2024-06-20 WO disclosed
US-20240132519-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2024-04-25 US disclosed
CN-115003727-B Curing catalyst, resin composition, sealing material, adhesive and cured product 纳美仕有限公司 2024-04-02 CN disclosed
EP-4328586-A1 FLUORESCENT STAINING METHOD OSAKA UNIVERSITY (JP) 2024-02-28 EP disclosed
EP-3354639-B1 PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND NIHON MEDIPHYSICS CO LTD (JP) 2024-02-21 EP disclosed
CN-117480390-A Fluorescent staining method 国立大学法人大阪大学 2024-01-30 CN disclosed
EP-4308570-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS Les Laboratoires Servier (FR) 2024-01-24 EP disclosed
CN-117425661-A Macrocyclic LRRK2 kinase inhibitors 法国施维雅药厂 2024-01-19 CN disclosed
EP-0302792-A2 Alkylaminoalkoxyphenyl derivatives, process of preparation and compositions containing the same SANOFI (FR) 1989-02-08 EP disclosed
EP-0292820-A2 3-Phenyl-2-styryl-pyrrolidines, their preparation and use BASF Aktiengesellschaft (DE) 1988-11-30 EP disclosed
EP-0292819-A2 5-Phenyl-1,2,3a,4,5,9b-hexahydro-3H-benz[e]indoles, their preparation and use as medicaments BASF Aktiengesellschaft (DE) 1988-11-30 EP disclosed
EP-0172059-B1 DERIVATIVES OF OXAAZAPHOSPHORINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ADIR (FR) 1988-04-20 EP disclosed
EP-0217700-A1 Benzimidazole derivatives, their preparation and their therapeutical use SYNTHELABO (FR) 1987-04-08 EP disclosed
EP-0172059-A1 Derivatives of oxaazaphosphorine, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1986-02-19 EP disclosed
EP-0056866-B1 PHENYLPIPERAZINE DERIVATIVES OF HETERYLPHENOLS AND HETARYLANILINES, THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS BASF Aktiengesellschaft (DE) 1985-06-19 EP disclosed
EP-0019172-B1 6-SUBSTITUTED 11-ALKYLENE-MORPHANTRIDINES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BASF Aktiengesellschaft (DE) 1983-07-13 EP disclosed
EP-0019172-A1 6-Substituted 11-alkylene-morphantridines, process for preparing them and pharmaceutical compositions containing them BASF Aktiengesellschaft (DE) 1980-11-26 EP disclosed
EP-0019157-A1 5,6-Dihydro-11-alkylene-morphanthridin-6-ones and process for their preparation BASF Aktiengesellschaft (DE) 1980-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240197923-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS NISCH, HLCS, CYP3A5 ALDH1A1 972/4885
US-20240132519-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 ALDH1A1 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.